Sight Sciences Clears FDA Hurdle for Next-Gen Glaucoma Device
Event summary
- Sight Sciences received FDA 510(k) clearance for OMNI Ultra Surgical System on August 4, 2026.
- The device is designed for canaloplasty and trabeculotomy to reduce intraocular pressure in primary open-angle glaucoma patients.
- OMNI Ultra features TruSync Plus technology for enhanced procedural control and single-pass canaloplasty.
- U.S. commercial launch planned for Q4 2026, building on OMNI platform with over 350,000 procedures performed worldwide.
The big picture
This clearance solidifies Sight Sciences' position in the minimally invasive glaucoma surgery (MIGS) space, where implant-free solutions are gaining traction. The OMNI platform's success—with over 350,000 procedures—demonstrates surgeon preference for comprehensive outflow pathway interventions. As glaucoma remains a leading cause of irreversible blindness, the ability to offer more precise and efficient treatments could drive further category expansion.
What we're watching
- Market Adoption
- How quickly OMNI Ultra gains surgeon preference over existing MIGS technologies.
- Revenue Impact
- Whether the premium features justify higher procedure pricing and accelerate platform growth.
- Competitive Positioning
- The pace at which Sight Sciences can maintain implant-free technology leadership amid emerging alternatives.
Related topics